We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

333 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 123 increasing their positions, 85 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 85

36% more call options, than puts

Call options by funds: $40.1M | Put options by funds: $29.5M

33% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 51

3% more funds holding

Funds holding: 322 → 333 (+11)

12.83% less ownership

Funds ownership: 75.87% → 63.04% (-13%)

16% less capital invested

Capital invested by funds: $1.58B → $1.33B (-$256M)

50% less funds holding in top 10

Funds holding in top 10: 8 → 4 (-4)

Holders
333
Holders Change
+11
Holders Change %
+3.42%
% of All Funds
4.05%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
68
Increased
123
Reduced
85
Closed
51
Calls
$40.1M
Puts
$29.5M
Net Calls
+$10.6M
Net Calls Change
-$11.1M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$36.7M
2
BlackRock
BlackRock
New York
+$35.3M
3
State Street
State Street
Massachusetts
+$35M
4
AIM
ARK Investment Management
Florida
+$18.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$14.3M

Top Sellers

1
MIC
Mubadala Investment Company
United Arab Emirates
-$63.4M
2
NHAS
Novo Holdings A/S
Denmark
-$38.7M
3
NC
Nvidia Corp
California
-$37.6M
4
Morgan Stanley
Morgan Stanley
New York
-$8.09M
5
BPCE
Bank Pictet & Cie (Europe)
Germany
-$7.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$9M +$4.65M +939,822 +74%
Bank of America
27
Bank of America
North Carolina
$8.64M +$4.4M +888,368 +73%
Capital Fund Management (CFM)
28
Capital Fund Management (CFM)
France
$7.28M +$5.22M +1,052,952 +145%
Millennium Management
29
Millennium Management
New York
$6.12M +$7.41M +1,495,839 New
Barclays
30
Barclays
United Kingdom
$6.01M -$401K -80,964 -5%
JP Morgan Chase
31
JP Morgan Chase
New York
$5.23M +$4.26M +859,326 +205%
Wells Fargo
32
Wells Fargo
California
$4.75M +$1.78M +359,625 +45%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$4.63M -$1.18M -238,074 -17%
N
34
Nuveen
North Carolina
$4.44M -$949K -191,511 -15%
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$4.43M +$4.81M +971,073 +858%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$3.96M +$1.08M +218,623 +29%
CFM
37
Comprehensive Financial Management
California
$3.85M – – –
Squarepoint
38
Squarepoint
New York
$3.63M +$4.39M +887,004 New
National Bank of Canada
39
National Bank of Canada
Quebec, Canada
$3.58M +$4.31M +870,484 +17,102%
HSBC Holdings
40
HSBC Holdings
United Kingdom
$3.37M +$3.42M +689,903 +537%
BNP Paribas Asset Management
41
BNP Paribas Asset Management
France
$3.27M +$3.94M +796,125 +26,960%
Swiss National Bank
42
Swiss National Bank
Switzerland
$2.95M +$494K +99,700 +16%
Balyasny Asset Management
43
Balyasny Asset Management
Illinois
$2.73M +$524K +105,726 +19%
AG
44
Algert Global
California
$2.72M +$3.29M +664,543 New
JF
45
Jump Financial
Illinois
$2.71M +$528K +106,551 +19%
Point72 Asset Management
46
Point72 Asset Management
Connecticut
$2.68M +$3.24M +654,211 New
VAS
47
Vestmark Advisory Solutions
Massachusetts
$2.47M -$80.7K -16,303 -3%
PBPIA
48
Pivotal bioVenture Partners Investment Advisor
California
$2.44M – – –
NFGH
49
Nan Fung Group Holdings
Hong Kong
$2.43M – – –
Stifel Financial
50
Stifel Financial
Missouri
$2.41M +$730K +147,353 +33%
1
2
3 4 5

RXRX Hedge Fund Activity: Q4 2025 in Review

333 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2025, worth a combined $1.33B — down 16% from $1.58B a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new RXRX positions and 51 closed out — a net gain of 17 holders — while 123 added to existing stakes and 85 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36.7M. The largest seller was Mubadala Investment Company, exiting entirely with an estimated $63.4M sold.

  • 333 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2025, up from 322 in Q3 2025.
  • Funds reported $1.33B of Recursion Pharmaceuticals stock for Q4 2025, down 16% quarter-over-quarter.
  • 68 funds opened new Recursion Pharmaceuticals positions in Q4 2025 and 51 closed out, a net change of +17 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $36.7M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2025 was Mubadala Investment Company, an estimated $63.4M sold.

Based on aggregated 13F filings for Q4 2025.